BF: Artificial Nipple and Duration of Breastfeeding (2008)
Blomquist HK, Jonesbo F, Serenius F, Persson LA. Supplementary feeding in the maternity ward shortens the duration of breastfeeding. Acta Paediatrics 1994; 83: 1,122-1,126.
PubMed ID: 7841722The aim of this prospective observational study was to elucidate the feeding routines at a maternity unit and to analyze the risk of not being breast fed at three months of age in relation to feeding patterns in the early neonatal period, while simultaneously taking into account a number of characteristics of the mother and child.
During the period from February to April 1990, 583 children were born at the
53 children who were treated entirely in the neonatal ward and the nine others who were discharged to other hospitals were excluded from the study.
Design
Prospective Cohort Study
Statistical Analysis
- The relative risks of not being breast-fed at three months of age were estimated by calculation of odds ratios (OR) and confidence limits (CL)
- When simultaneous adjustments were made for several potential confounders, multiple logistic regression analysis was used using EGRET software program.
Timing of Measurements
- Information regarding pregnancy, delivery and early neonatal feeding was registered by the maternity unit staff and cross-checked by a pediatrician when the mother and baby were discharged from the hospital
- A questionnaire regarding feeding patterns at one, two, three and four months was prospectively completed by the parents
- Missing information was obtained by telephone interviews
- One-quarter of the children received supplementary feeds on the third day of life, the indications for this being birth weight less than 3.0kg, maternal diabetes or gestational diabetes, “insufficient amounts of milk” or fussiness.
- Exclusively breast-fed: Infant received only breast milk from its mother, or expressed breast milk, and no other liquids or solids, with the exception of drops or syrup containing vitamins, mineral supplements or medicines
- Breast-fed: Infant received breast milk, but was not allowed to receive any food or liquid including non-human milk
- Supplementary donor’s milk: Infant received human milk from the pooled milk bank.
Independent Variables
- Mother’s age (years)
- Mother smoking
- Earlier births
- Delivery
- Gestational age (weeks)
- Birth weight (g)
- Sex
- Admitted neonatal ward initially
- Supplementary feeding
- Used breast pump
- Used oxytocin spray
- Weight loss >=10%.
Control Variables
All independent variables were in multiple logistic regression model.
Initial N
583
Attrition (final N)
521 children (243 boys and 278 girls). Note: Feeding information after the neonatal period were missing in 6%.
Age
See table 2
Ethnicity
Not described
Other relevant demographics
Location
Umea, Sweden
Table 1: Proportion of children receiving supplementary donor’s milk or formula in relation to different indications (percentage of total number of children for each day).
Day | ||||||
Indication | 1 | 2 | 3 | 4 | 5 | 6 |
Birth weight<3kg | 2.9 | 4.7 | 5.5 | 3.2 | 1.9 | 0.0 |
Birth weight>4.5kg | 0.2 | 0.4 | 0.4 | 0.4 | 0.2 | 0.9 |
Initial weight loss | 0.0 | 0.2 | 1.6 | 4.4 | 2.6 | 0.9 |
Maternal diabetes or gestational diabetes | 5.7 | 6.0 | 5.5 | 3.6 | 1.4 | 0.9 |
Jitteriness | 0.2 | 1.0 | 1.2 | 0.4 | 0.0 | 0.0 |
Fussiness | 0.4 | 1.4 | 2.3 | 1.2 | 0.5 | 0.9 |
Insufficient amount of milk | 2.0 | 2.1 | 3.7 | 3.4 | 5.6 | 8.4 |
Other, unknown | 1.2 | 1.8 | 2.2 | 2.4 | 2.8 | 6.7 |
Percent of children receiving supplementary feeding | 12.5 | 17.5 | 22.3 | 18.6 | 15.0 | 18.7 |
Total number of children in the maternity unita
|
511 | 513 | 511 | 505 | 426 | 225 |
a 35 children were partly treated in the neonatal unit, usually the first one to two days.
In the bi-variate analysis, an increased risk of not being breast-fed at three months was related to young maternal age, smoking, Cesarean section, supplementation with door’s milk or formula at the maternity unit, the use of oxytocin spray and an initial weight loss ≥10% of birth weight.
Characteristics Mother’s age (years)
Many of these factors in Table 2 are associated with each other. In order to control for confounding, multiple logistic regression including all factors in Table 2 were performed. After adjustment there was a significant independent increased risk of not being breast-fed at three months in relationship to maternal age (<25 years OR 4.2, 95% CL 2.0-8.5), maternal smoking (OR 4.0, 95% CL 2.1-7.4), neonatal feeding (supplements OR 3.9,95% CL 2.1-7.2) and initial weight loss ≥10% OR 2.8, 95% CL 1.4-5.8).
Other Findings
The relative risk of not being breast fed at three months in relation to feeding in the maternity unit and initial weight loss(reference group=those exclusively breast fed with an initial weight loss of less than 10% of birth weight, OR 1.0) was analyzed.
There was an interaction between initial weight loss and feeding pattern at the maternity unit and the risk of not being breast-fed at three months. The risk of not being breast-fed was almost seven times higher for infants who were supplemented and had an initial weight loss >=10% of birth weight, compared with unsupplemented infants with less weight loss.
- Giving supplementary donor’s milk or formula during early neonatal period increased the risk of a short duration of breastfeeding even after adjustment for initial weight loss and other factors examined
- Supplementary feeding in the maternity unit was associated with an increased risk of early cessation of breastfeeding. The authors recommended that supplementary feeding be given with greater restrictively to healthy newborn children.
Limitations
- Maternal education which has been shown to be associated with breastfeeding was not included in the analysis; smoking, a factor strongly associated with education was examined
- The association between supplementation and non-breastfeeding was not weakened but became stronger when the different potential confounders were accounted for. This may have indicated a casual relationship; however, the mother’s confidence and willingness to continue breastfeeding was not assessed.
- The supplements were planned to be prescribed by pediatricians but some children received supplementation for no declared reason
- The routines for supplementation were rather liberal and were later revised in accordance with international recommendations.
Analytical longitudinal surveys refer to what epidemiologists term prospective or cohort studies. A Cohort Study is a study in which patients who presently have a certain condition and/or receive a particular treatment are followed over time and compared with another group who are not affected by the condition under investigation. Studies of this kind provide a better opportunity than one-time cross-sectional studies to examine whether certain behaviors do in fact lead to (or cause) the disease.
The limitations and critique of the study, as stated by the authors appear to be very appropriate.
Quality Criteria Checklist: Primary Research
|
|||
Relevance Questions | |||
1. | Would implementing the studied intervention or procedure (if found successful) result in improved outcomes for the patients/clients/population group? (Not Applicable for some epidemiological studies) | Yes | |
2. | Did the authors study an outcome (dependent variable) or topic that the patients/clients/population group would care about? | Yes | |
3. | Is the focus of the intervention or procedure (independent variable) or topic of study a common issue of concern to dieteticspractice? | Yes | |
4. | Is the intervention or procedure feasible? (NA for some epidemiological studies) | Yes | |
Validity Questions | |||
1. | Was the research question clearly stated? | Yes | |
1.1. | Was (were) the specific intervention(s) or procedure(s) [independent variable(s)] identified? | Yes | |
1.2. | Was (were) the outcome(s) [dependent variable(s)] clearly indicated? | Yes | |
1.3. | Were the target population and setting specified? | Yes | |
2. | Was the selection of study subjects/patients free from bias? | Yes | |
2.1. | Were inclusion/exclusion criteria specified (e.g., risk, point in disease progression, diagnostic or prognosis criteria), and with sufficient detail and without omitting criteria critical to the study? | Yes | |
2.2. | Were criteria applied equally to all study groups? | Yes | |
2.3. | Were health, demographics, and other characteristics of subjects described? | Yes | |
2.4. | Were the subjects/patients a representative sample of the relevant population? | Yes | |
3. | Were study groups comparable? | Yes | |
3.1. | Was the method of assigning subjects/patients to groups described and unbiased? (Method of randomization identified if RCT) | N/A | |
3.2. | Were distribution of disease status, prognostic factors, and other factors (e.g., demographics) similar across study groups at baseline? | N/A | |
3.3. | Were concurrent controls or comparisons used? (Concurrent preferred over historical control or comparison groups.) | N/A | |
3.4. | If cohort study or cross-sectional study, were groups comparable on important confounding factors and/or were preexisting differences accounted for by using appropriate adjustments in statistical analysis? | Yes | |
3.5. | If case control study, were potential confounding factors comparable for cases and controls? (If case series or trial with subjects serving as own control, this criterion is not applicable.) | N/A | |
3.6. | If diagnostic test, was there an independent blind comparison with an appropriate reference standard (e.g., "gold standard")? | N/A | |
4. | Was method of handling withdrawals described? | Yes | |
4.1. | Were follow-up methods described and the same for all groups? | Yes | |
4.2. | Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described for each group? (Follow up goal for a strong study is 80%.) | Yes | |
4.3. | Were all enrolled subjects/patients (in the original sample) accounted for? | Yes | |
4.4. | Were reasons for withdrawals similar across groups? | N/A | |
4.5. | If diagnostic test, was decision to perform reference test not dependent on results of test under study? | N/A | |
5. | Was blinding used to prevent introduction of bias? | ??? | |
5.1. | In intervention study, were subjects, clinicians/practitioners, and investigators blinded to treatment group, as appropriate? | N/A | |
5.2. | Were data collectors blinded for outcomes assessment? (If outcome is measured using an objective test, such as a lab value, this criterion is assumed to be met.) | ??? | |
5.3. | In cohort study or cross-sectional study, were measurements of outcomes and risk factors blinded? | No | |
5.4. | In case control study, was case definition explicit and case ascertainment not influenced by exposure status? | N/A | |
5.5. | In diagnostic study, were test results blinded to patient history and other test results? | N/A | |
6. | Were intervention/therapeutic regimens/exposure factor or procedure and any comparison(s) described in detail? Were interveningfactors described? | Yes | |
6.1. | In RCT or other intervention trial, were protocols described for all regimens studied? | N/A | |
6.2. | In observational study, were interventions, study settings, and clinicians/provider described? | Yes | |
6.3. | Was the intensity and duration of the intervention or exposure factor sufficient to produce a meaningful effect? | N/A | |
6.4. | Was the amount of exposure and, if relevant, subject/patient compliance measured? | N/A | |
6.5. | Were co-interventions (e.g., ancillary treatments, other therapies) described? | N/A | |
6.6. | Were extra or unplanned treatments described? | N/A | |
6.7. | Was the information for 6.4, 6.5, and 6.6 assessed the same way for all groups? | N/A | |
6.8. | In diagnostic study, were details of test administration and replication sufficient? | N/A | |
7. | Were outcomes clearly defined and the measurements valid and reliable? | Yes | |
7.1. | Were primary and secondary endpoints described and relevant to the question? | Yes | |
7.2. | Were nutrition measures appropriate to question and outcomes of concern? | Yes | |
7.3. | Was the period of follow-up long enough for important outcome(s) to occur? | Yes | |
7.4. | Were the observations and measurements based on standard, valid, and reliable data collection instruments/tests/procedures? | Yes | |
7.5. | Was the measurement of effect at an appropriate level of precision? | Yes | |
7.6. | Were other factors accounted for (measured) that could affect outcomes? | Yes | |
7.7. | Were the measurements conducted consistently across groups? | Yes | |
8. | Was the statistical analysis appropriate for the study design and type of outcome indicators? | Yes | |
8.1. | Were statistical analyses adequately described and the results reported appropriately? | Yes | |
8.2. | Were correct statistical tests used and assumptions of test not violated? | Yes | |
8.3. | Were statistics reported with levels of significance and/or confidence intervals? | Yes | |
8.4. | Was "intent to treat" analysis of outcomes done (and as appropriate, was there an analysis of outcomes for those maximally exposed or a dose-response analysis)? | Yes | |
8.5. | Were adequate adjustments made for effects of confounding factors that might have affected the outcomes (e.g., multivariate analyses)? | Yes | |
8.6. | Was clinical significance as well as statistical significance reported? | Yes | |
8.7. | If negative findings, was a power calculation reported to address type 2 error? | N/A | |
9. | Are conclusions supported by results with biases and limitations taken into consideration? | Yes | |
9.1. | Is there a discussion of findings? | Yes | |
9.2. | Are biases and study limitations identified and discussed? | Yes | |
10. | Is bias due to study's funding or sponsorship unlikely? | Yes | |
10.1. | Were sources of funding and investigators' affiliations described? | Yes | |
10.2. | Was the study free from apparent conflict of interest? | Yes | |